Leuven-Haifa High-Resolution Fundus Image Dataset for Retinal Blood Vessel Segmentation and Glaucoma Diagnosis.

The Leuven-Haifa dataset contains 240 disc-centered fundus images of 224 unique patients (75 patients with normal tension glaucoma, 63 patients with high tension glaucoma, 30 patients with other eye diseases and 56 healthy controls) from the University Hospitals of Leuven. The arterioles and venules of these images were both annotated by master students in medicine and corrected by a senior annotator. All senior segmentation corrections are provided as well as the junior segmentations of the test set. An open-source toolbox for the parametrization of segmentations was developed. Diagnosis, age, sex, vascular parameters as well as a quality score are provided as metadata. Potential reuse is envisioned as the development or external validation of blood vessels segmentation algorithms or study of the vasculature in glaucoma and the development of glaucoma diagnosis algorithms. The dataset is available on the KU Leuven Research Data Repository (RDR).

The NEVERMIND e-health system in the treatment of depressive symptoms among patients with severe somatic conditions: A multicentre, pragmatic randomised controlled trial.

Background: This study assessed the effectiveness of the NEVERMIND e-health system, consisting of a smart shirt and a mobile application with lifestyle behavioural advice, mindfulness-based therapy, and cognitive behavioural therapy, in reducing depressive symptoms among patients diagnosed with severe somatic conditions. Our hypothesis was that the system would significantly decrease the level of depressive symptoms in the intervention group compared to the control group. Methods: This pragmatic, randomised controlled trial included 425 patients diagnosed with myocardial infarction, breast cancer, prostate cancer, kidney failure, or lower limb amputation. Participants were recruited from hospitals in Turin and Pisa (Italy), and Lisbon (Portugal), and were randomly assigned to either the NEVERMIND intervention or to the control group. Clinical interviews and structured questionnaires were administered at baseline, 12 weeks, and 24 weeks. The primary outcome was depressive symptoms at 12 weeks measured by the Beck Depression Inventory II (BDI-II). Intention-to-treat analyses included 425 participants, while the per-protocol analyses included 333 participants. This trial is registered in the German Clinical Trials Register, DRKS00013391. Findings: Patients were recruited between Dec 4, 2017, and Dec 31, 2019, with 213 assigned to the intervention and 212 to the control group. The sample had a mean age of 59·41 years (SD=10·70), with 44·24% women. Those who used the NEVERMIND system had statistically significant lower depressive symptoms at the 12-week follow-up (mean difference=-3·03, p<0·001; 95% CI -4·45 to -1·62) compared with controls, with a clinically relevant effect size (Cohen's d=0·39). Interpretation: The results of this study show that the NEVERMIND system is superior to standard care in reducing and preventing depressive symptoms among patients with the studied somatic conditions. Funding: The NEVERMIND project received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 689691.

Retinal imaging biomarkers of neurodegenerative diseases.

The timely detection of neurodegenerative diseases is central to improving clinical care as well as enabling the development and deployment of disease-modifying therapies. Retinal imaging is emerging as a method to detect features of a number of neurodegenerative diseases, given the anatomical and functional similarities between the retina and the brain. This review provides an overview of the current status of retinal imaging biomarkers of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Lewy body dementia, frontotemporal dementia, Huntington's disease and multiple sclerosis. Whilst research findings are promising, efforts to harmonise study designs and imaging methods will be important in translating these findings into clinical care. Doing so may mean that eye care providers will play important roles in the detection of a variety of neurodegenerative diseases in future.

Bayesian Transfer Learning for the Prediction of Self-reported Well-being Scores.

Predicting the severity and onset of depressive symptoms is of great importance. User-specific models have better performance than a general model but require significant amounts of training data from each individual, which is often impractical to obtain. Even when this is possible, there is a significant lag between the beginning of the data-collection phase and when the system is completely trained and thus able to start making useful predictions. In this study, we propose a transfer learning Bayesian modelling method based on a Markov Chain Monte Carlo (MCMC) sampler and Bayesian model averaging for dealing with the challenge of building user-specific predictive models able to make predictions of self-reported well-being scores with limited sparse training data. The evaluation of our method using real-world data collected within the NEVERMIND project showed a better predictive performance for the transfer learning model compared to conventional learning with no transfer.